Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 4

The DOI matches its Crossref record; the references it cites are not checked yet.

What Form of RSV Protection Do Women Prefer: Maternal Vaccination or Infant Immunisation? A Cross-Sectional Survey in Europe

Mendes, Diana, Kang, Malvin, Law, Amy·2026·Vaccines
DOI 10.3390/vaccines14030238
Open this paper in CoChat — free account

Abstract

Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections in infants/newborns, sometimes requiring hospitalisation. Two immunisation options are approved in Europe: maternal vaccination and infant immunisation. Success of the immunisation programme depends on uptake—however, understanding of women’s immunisation preferences remains limited. This study evaluated women’s knowledge of RSV, RSV immunisation intentions, and factors influencing immunisation decisions in Finland, France, Germany, Italy, Spain, and the UK. Methods: A cross-sectional survey was conducted between November and December 2024 with 740 women across the selected countries. Participants included women who were pregnant, trying to conceive, or previously pregnant within the year prior to survey. Participants were asked about their knowledge, intentions, and preferences regarding RSV immunisation. Results: Familiarity with RSV was lower than that for COVID-19 and influenza (45% vs. 86% and 85%). Among those pregnant or trying to conceive, 68% reported they were likely to initiate an RSV immunisation discussion with a healthcare provider and 21% reported they were unlikely to do so. The majority (76%) also reported they were likely to accept RSV vaccination if recommended by a healthcare provider. Overall, 52% preferred maternal vaccination over infant immunisation. Among the 82% of women who would consider RSV immunisation and had a preference for immunisation method, 68% favoured maternal vaccination. Conclusions: RSV immunisation acceptance among European women is high and a majority prefer maternal vaccination over infant immunisation. This indicates potential for RSV immunisation to achieve high uptake when women have access to immunisation methods aligned with their preferences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/vaccines14030238

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

Cited by 4

Research works printed but not linked: 28

  1. Spreeuwenberg, 2023, Burden of Respiratory Syncytial Virus in the European Union: Estimation of RSV-Associated Hospitalizations in Children under 5 Years, J. Infect. Dis., 228, 1528, 10.1093/infdis/jiad188 · DOI
  2. Du, 2023, Global Burden and Trends of Respiratory Syncytial Virus Infection across Different Age Groups from 1990 to 2019: A Systematic Analysis of the Global Burden of Disease 2019 Study, Int. J. Infect. Dis., 135, 70, 10.1016/j.ijid.2023.08.008 · DOI
  3. Li, 2022, Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis, Lancet, 399, 2047, 10.1016/S0140-6736(22)00478-0 · DOI · Paper page
  4. Hall, 2009, The burden of respiratory syncytial virus infection in young children, N. Engl. J. Med., 360, 588, 10.1056/NEJMoa0804877 · DOI · Paper page
  5. Binns, 2022, Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions, J. Paediatr. Child. Health, 58, 1741, 10.1111/jpc.16197 · doi:10.1111/jpc.16197
  6. Sommer, 2011, Risk factors for severe respiratory syncytial virus lower respiratory tract infection, Open Microbiol. J., 5, 144, 10.2174/1874285801105010144 · DOI · Paper page
  7. Bhore, 2010, Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis, Pediatrics, 126, e1453, 10.1542/peds.2010-0507 · DOI · Paper page
  8. Heemskerk, 2025, Assessing the Impact of Non-Pharmaceutical Interventions During the COVID-19 Pandemic on RSV Seasonality in Europe, Influenza Other Respir. Viruses, 19, e70066, 10.1111/irv.70066 · doi:10.1111/irv.70066
  9. Sinnathamby, 2023, Seasonal and Inter-seasonal RSV Activity in the European Region during the COVID-19 Pandemic from Autumn 2020 to Summer 2022, Influenza Other Respir. Viruses, 17, e13219, 10.1111/irv.13219 · doi:10.1111/irv.13219
  10. Kampmann, 2023, Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants, N. Engl. J. Med., 388, 1451, 10.1056/NEJMoa2216480 · DOI · Paper page
  11. Pahud, 2025, Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial, Obstet. Gynecol., 145, 157, 10.1097/AOG.0000000000005816 · doi:10.1097/aog.0000000000005816
  12. Munro, 2025, 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): A randomised, controlled, phase 3b trial, Lancet Child Adolesc. Health, 9, 404, 10.1016/S2352-4642(25)00102-6 · doi:10.1016/s2352-4642(25)00102-6
  13. Drysdale, 2023, Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants, N. Engl. J. Med., 389, 2425, 10.1056/NEJMoa2309189 · DOI · Paper page
  14. Campbell, 2025, Respiratory Syncytial Virus (RSV): Recent Advances in Preventative Strategies and Visions for the Future, Paediatr. Child. Health, 35, 341, 10.1016/j.paed.2025.07.005 · doi:10.1016/j.paed.2025.07.005
  15. Giersing, 2019, Meeting Report: WHO Consultation on Respiratory Syncytial Virus (RSV) Vaccine Development, Geneva, 25–26 April 2016, Vaccine, 37, 7355, 10.1016/j.vaccine.2017.02.068 · DOI
  16. Razai, M.S., Mansour, R., Ravindran, P., Freeman, S., Mason-Apps, C., Morris, J., Majeed, A., Ussher, M., Hargreaves, S., and Oakeshott, P. (2024). Facilitators and Barriers to Vaccination Uptake in Pregnancy: A Qualitative Systematic Review. PLoS ONE, 19. · DOI
  17. Pavlovic, 2022, Factors Influencing Healthcare Professionals’ Confidence in Vaccination in Europe: A Literature Review, Hum. Vaccines Immunother., 18, 2041360, 10.1080/21645515.2022.2041360 · DOI
  18. Sanni, A., Ibrahim, N., Tilley, D., Bontha, S., McMorrow, A., and Philip, R.K. (2025). Maternal Vaccination as an Integral Part of Life-Course Immunization: A Scoping Review of Uptake, Barriers, Facilitators, and Vaccine Hesitancy for Antenatal Vaccination in Ireland. Vaccines, 13. · DOI
  19. Harteveld, 2025, Respiratory Syncytial Virus (RSV) Prevention: Perception and Willingness of Expectant Parents in the Netherlands, Vaccine, 44, 126541, 10.1016/j.vaccine.2024.126541 · DOI
  20. Broad, 2025, An England-Wide Survey on Attitudes towards Antenatal and Infant Immunisation against Respiratory Syncytial Virus amongst Pregnant and Post-Partum Women, Vaccine, 62, 127482, 10.1016/j.vaccine.2025.127482 · DOI · Paper page
  21. McCormack, 2024, Maternal Awareness, Acceptability and Willingness towards Respiratory Syncytial Virus (RSV) Vaccination during Pregnancy in Ireland, Immun. Inflamm. Dis., 12, e1257, 10.1002/iid3.1257 · DOI · Paper page
  22. Williams, 2025, Maternal Views on RSV Vaccination during the First Season of Implementation in England and Scotland, Lancet Infect. Dis., 25, e135, 10.1016/S1473-3099(25)00060-X · doi:10.1016/s1473-3099(25)00060-x
  23. Langedijk, 2025, Preferences of Dutch Parents and Expectant Parents for Respiratory Syncytial Virus Prevention Strategies: A Discrete Choice Experiment, Infect. Dis. Ther., 14, 2583, 10.1007/s40121-025-01214-2 · doi:10.1007/s40121-025-01214-2
  24. Paulson, 2025, Protecting Against Respiratory Syncytial Virus: An Online Questionnaire Study Exploring UK Parents’ Acceptability of Vaccination in Pregnancy or Monoclonal Antibody Administration for Infants, Pediatr. Infect. Dis. J., 44, S158, 10.1097/INF.0000000000004632 · DOI
  25. Holland, 2024, Parental Awareness and Attitudes towards Prevention of Respiratory Syncytial Virus in Infants and Young Children in Australia 2023, Acta Paediatr., 113, 786, 10.1111/apa.17127 · DOI
  26. Maculaitis, 2024, A Latent Class Analysis of Factors Influencing Preferences for Infant Respiratory Syncytial Virus (RSV) Preventives among Pregnant People in the United States, Hum. Vaccines Immunother., 20, 2358566, 10.1080/21645515.2024.2358566 · DOI
  27. Beusterien, K.M., Law, A.W., Maculaitis, M.C., Will, O., Kopenhafer, L., Olsen, P., Hauber, B., Vietri, J.T., Cappelleri, J.C., and Coulter, J.R. (2024). Healthcare Providers’ and Pregnant People’s Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus. Vaccines, 12. · DOI
  28. Gagnon, 2025, Factors Influencing Acceptance of RSV Immunization for Newborns among Pregnant Individuals: A Mixed-Methods Study, Vaccine, 55, 127062, 10.1016/j.vaccine.2025.127062 · doi:10.1016/j.vaccine.2025.127062

Metadata

Authors
Mendes, D., Kang, M., & Law, A.
Venue
Vaccines
Publisher
MDPI AG
Published
2026-03-05
Volume
14
Issue
3
Pages
238
ISSN
2076-393X
DOI
10.3390/vaccines14030238
Cited by
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
Pfizer Inc.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What Form of RSV Protection Do Women Prefer: Maternal Vaccination or Infant Immunisation? A Cross-Sectional Survey in Europe. https://app.cochat.ai/papers/10.3390/vaccines14030238
The paper
Mendes, D., Kang, M., & Law, A. (2026). What Form of RSV Protection Do Women Prefer: Maternal Vaccination or Infant Immunisation? A Cross-Sectional Survey in Europe. Vaccines. https://doi.org/10.3390/vaccines14030238

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.